What we know
Strong, replicated evidence — usually meta-analyses or international consensus. Unlikely to change much. What these labels meanReplicated, large, or agreed by international consensus.
ADHD is a valid neurodevelopmental condition found across countries and cultures.
Faraone et al. 2021
- Consensus statement Faraone SV, Banaschewski T, Coghill D, et al. (80 authors) (2021). The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder. Neuroscience & Biobehavioral Reviews, 128, 789–818. Open source ↗Only included findings from meta-analyses or studies with more than 2,000 participants.
It is highly heritable (~74%) and highly polygenic — thousands of variants, each with a tiny effect.
Faraone et al. 2019 +1
- Narrative review Faraone SV, Larsson H (2019). Genetics of attention deficit hyperactivity disorder. Molecular Psychiatry, 24, 562–575. Open source ↗Mean heritability ≈ 74% across twin studies.
- Cohort / register study Demontis D, Walters GB, Athanasiadis G, et al. (2023). Genome-wide analyses of ADHD identify 27 risk loci, refine the genetic architecture and implicate several cognitive domains. Nature Genetics, 55, 198–208. Open source ↗38,691 people with ADHD and 186,843 controls; mostly European ancestry.
It often persists into adulthood: about 2.6% of adults have persistent ADHD.
Song et al. 2021
- Meta-analysis Song P, et al. (2021). The prevalence of adult attention-deficit hyperactivity disorder: a global systematic review and meta-analysis. Journal of Global Health, 11, 04009. Open source ↗Persistent adult ADHD 2.58%; symptomatic adult ADHD 6.76%.
Medication reduces core symptoms in the short term for many children and adults.
Cortese et al. 2018 +1
- Meta-analysis Cortese S, Adamo N, Del Giovane C, et al. (2018). Comparative efficacy and tolerability of medications for ADHD in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry, 5(9), 727–738. Open source ↗133 double-blind randomised trials; short-term outcomes (about 12 weeks).
- Meta-analysis Ostinelli EG, et al. (senior author: Cortese S) (2025). Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis. The Lancet Psychiatry. Open source ↗Adults only. Short-term symptom benefits for stimulants and atomoxetine; little evidence on quality of life or long-term outcomes.
Emotional dysregulation is common in ADHD, even though it isn’t a diagnostic criterion.
Shaw et al. 2014 +1
- Narrative review Shaw P, Stringaris A, Nigg J, Leibenluft E (2014). Emotion dysregulation in attention deficit hyperactivity disorder. American Journal of Psychiatry, 171(3), 276–293. Open source ↗Emotion dysregulation in about 25–45% of children and 30–70% of adults with ADHD.
- Meta-analysis Beheshti A, Chavanon M-L, Christiansen H (2020). Emotion dysregulation in adults with attention deficit hyperactivity disorder: a meta-analysis. BMC Psychiatry, 20, 120. Open source ↗13 studies, 2,535 participants; large difference (g ≈ 1.17).
Girls and women are diagnosed later and less often than boys and men.
Martin et al. 2024
- Cohort / register study Martin J, et al. (2024). Sex differences in attention-deficit hyperactivity disorder diagnosis and clinical care: a national study of population healthcare records in Wales. Journal of Child Psychology and Psychiatry, 65(12), 1648–1658. Open source ↗16,458 people diagnosed with ADHD.